Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LivaNova (LIVN) Asset Writedowns and Impairment (2015 - 2024)

LivaNova recorded quarterly Asset Writedowns and Impairment of -$5.8 million in Q4 2024, down 200.31% quarter-over-quarter from $5.8 million in Q2 2024, and down 145.7% year-over-year from $12.6 million in Q1 2024.

LivaNova's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at -$5.8 million for Q4 2024.

  • In Q4 2024, Asset Writedowns and Impairment fell 145.7% year-over-year to -$5.8 million; the TTM figure through Dec 2024 stood at $12.6 million (down 34.98% YoY), while the FY2023 annual figure was $12.6 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment came in at -$5.8 million for Q4 2024 at LivaNova, down from $5.8 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $12.6 million in Q4 2023 to a low of -$5.8 million in Q4 2024.
  • A 3-year average of $4.8 million and a median of $6.3 million in 2020 frame the typical range for Asset Writedowns and Impairment.
  • Across the five-year window, Asset Writedowns and Impairment slumped 92.4% in 2020 and sank 145.7% in 2024, its largest moves.
  • LivaNova's Asset Writedowns and Impairment stood at $6.8 million in 2020, then jumped by 86.65% to $12.6 million in 2023, then tumbled by 145.7% to -$5.8 million in 2024.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$5.8 million, $5.8 million, and $12.6 million for Q4 2024, Q2 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 LivaNova 4.03 Bn 3.45 Bn 243.75 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -5.77 Mn
Dec 31, 2024 -5.77 Mn
Jun 30, 2024 5.75 Mn
Jun 30, 2024 5.75 Mn
Dec 31, 2023 12.62 Mn
Dec 31, 2023 12.62 Mn
Dec 31, 2020 6.76 Mn
Dec 31, 2020 6.76 Mn
Dec 31, 2019 89.00 Mn
Dec 31, 2019 89.00 Mn
Jun 30, 2019 50.30 Mn
Jun 30, 2019 50.30 Mn
Dec 31, 2018 567,000.00
Dec 31, 2018 567,000.00
Dec 31, 2016 -19.38 Mn
Dec 31, 2016 -19.38 Mn
Sep 30, 2016 19.32 Mn
Sep 30, 2016 19.32 Mn
Jul 24, 2015 2.06 Mn
Jul 24, 2015 2.06 Mn
Apr 24, 2015 448,000.00
Apr 24, 2015 448,000.00